Oppenheimer downgraded RxSight (RXST) to Perform from Outperform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight price target lowered to $9 from $17 at Stifel
- RxSight downgraded to Neutral from Buy at BTIG
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- Closing Bell Movers: AES Corp jumps 14% on takeover possibility